In addition, the Shh inhibitor cyclopamine significantly decreased the viability and Gli-1 translocation of IL-6-treated HL-60 cells, hinting that blocking the Shh pathway may be a potential strategy for AML treatment. Here, SHH is linked to acute myeloid leukemia.